[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. reported an insider equity transaction involving its Chief Legal Officer. On 11/14/2025, 184 shares of common stock were disposed of at a price of $2.24 per share. The filing explains that these shares were withheld by the company to satisfy mandatory tax withholding upon the vesting of restricted stock units, rather than being sold in an open-market transaction.

After this tax withholding event, the reporting officer beneficially owns 34,555 shares of Acrivon Therapeutics common stock, held directly. The Form 4 is filed by a single reporting person and reflects routine equity compensation administration for the officer role.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		F(1)		184	D	$2.24	34,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) disclose in this Form 4?

The filing reports that the Chief Legal Officer of Acrivon Therapeutics, Inc. had 184 shares of common stock disposed of on 11/14/2025 at $2.24 per share, in connection with equity compensation.

Why were 184 ACRV shares disposed of by the Chief Legal Officer?

The 184 shares were withheld by the issuer to satisfy the mandatory tax withholding requirement that arose when restricted stock units vested, according to the explanation of responses.

How many Acrivon Therapeutics (ACRV) shares does the officer own after this transaction?

Following the reported transaction, the Chief Legal Officer beneficially owns 34,555 shares of Acrivon Therapeutics common stock, held in direct ownership.

What is the officer’s role and relationship to Acrivon Therapeutics (ACRV)?

The reporting person is an officer of Acrivon Therapeutics, Inc., serving as the company’s Chief Legal Officer, as indicated in the relationship section.

Was this ACRV Form 4 filed by more than one reporting person?

No. The report indicates that the Form 4 is filed by one reporting person, not by a group or multiple filers.

Does this Form 4 reflect trading under a Rule 10b5-1 plan for ACRV shares?

The form includes a checkbox for transactions made under a Rule 10b5-1(c) trading plan, but the provided content does not indicate that this box was checked for the reported transaction.